XML 47 R8.htm IDEA: XBRL DOCUMENT
v3.21.1

Basis of presentation | 12 Months Ended
--- | ---
Dec. 31, 2020
Text Block [Abstract] |
Basis of presentation |
2. | Basis of presentation
The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (“IFRS IC”). The consolidated financial statements are presented in Euro. Amounts are stated in thousands of Euros, unless otherwise indicated. The Group had a non-controlling interest, representing approximately 3.96% of the Group’s Immatics US, Inc. subsidiary as of December 31, 2019 and 2018. On July 1, 2020 and as part of the ARYA Merger, the non-controlling interest of MD Anderson in Immatics US, Inc. was exchanged for ordinary shares in Immatics N.V. See note 3 for further details. Short-term deposits, which have an original maturity between three and nine months, were previously classified within Other current assets and have been retrospectively presented as a separate line item, Other financial assets, within the Statement of Financial Position. This change resulted in a reclassification of €16.0 million as of December 31, 2019. This change in presentation was made after review of the Group’s financial statements subsequent to the ARYA Merger to ensure better comparability of the financial statements with peer companies and provide more relevant presentation within the Group’s financial statements.
2.1 | Going concern
Since inception, the Group’s activities have consisted primarily of raising capital and performing research and development activities to advance its technologies. The Group is still in the development phase and has not yet marketed any products commercially. Immatics’ ongoing success depends on the successful development and regulatory approval of its products and its ability to finance operations. The Group will seek additional funding to reach its development and commercialization objectives. The Group plans to seek funds through further private or public equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. However, Immatics’ cash and cash equivalents as well as short-term deposits will be sufficient to fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date and expect a cash reach for at least twelve months. The accompanying consolidated financial statements have been prepared on a going concern basis. This contemplates the Group will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going concern.
2.2 | Correction of classification of Statement of Cash Flows
During the third quarter of 2020, the Group identified and corrected the classification of short-term deposits with an original maturity dates between three and nine months within the Statement of Cash Flows which resulted in a misclassification within the Statement of Cash Flows since 2018. The Company has evaluated the effect of this misclassification, both qualitatively and quantitatively, and concluded that the correction did not have a material impact on, nor require amendment of, any previously filed financial statements. In the Statement of Cash Flows, the changes in short-term deposits were previously classified as (Increase) decrease in other assets within operating activities and has been retrospectively corrected and presented as separate line items within investing activities. This correction of classification resulted in the following impact to the Statement of Cash Flows:
|  | Year ended December 31, 2019 |  |  | Year ended December 31, 2018 |
|  | As reported |  |  | Adjustment |  |  | As revised |  |  | As reported |  |  | Adjustment |  |  | As revised |
(Increase) decrease in other assets |  |  | (4,419 | ) |  |  | 2,922 |  |  |  | (1,497 | ) |  |  | (7,493 | ) |  |  | 13,101 |  |  |  | 5,608 |
Net cash provided by operating activities |  |  | 68,045 |  |  |  | 2,922 |  |  |  | 70,967 |  |  |  | 7,583 |  |  |  | 13,101 |  |  |  | 20,684 |
Cash paid for investments classified in Other financial assets |  |  | — |  |  |  | (20,473 | ) |  |  | (20,473 | ) |  |  | — |  |  |  | (13,101 | ) |  |  | (13,101 | )
Cash received from maturity of investments classified in Other financial assets |  |  | — |  |  |  | 17,551 |  |  |  | 17,551 |  |  |  | — |  |  |  | — |  |  |  | — |
Net cash used in investing activities |  |  | (2,137 | ) |  |  | (2,922 | ) |  |  | (5,059 | ) |  |  | (413 | ) |  |  | (13,101 | ) |  |  | (13,514 | )
Total effect on Cash Flow |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
|  | Three months ended March 31, 2020 |  |  | Six months ended June 30, 2020 |
|  | As reported |  |  | Adjustment |  |  | As revised |  |  | As reported |  |  | Adjustment |  |  | As revised |
(Increase) decrease in other assets |  |  | (17,209 | ) |  |  | 16,836 |  |  |  | (373 | ) |  |  | 14,917 |  |  |  | (16,023 | ) |  |  | (1,106 | )
Net cash provided by/ (used in) operating activities |  |  | (28,286 | ) |  |  | 16,836 |  |  |  | (11,450 | ) |  |  | (11,716 | ) |  |  | (16,023 | ) |  |  | (27,739 | )
Cash paid for investments classified in Other financial assets |  |  | — |  |  |  | (32,859 | ) |  |  | (32,859 | ) |  |  | — |  |  |  | (32,859 | ) |  |  | (32,859 | )
Cash received from maturity of investments classified in Other financial assets |  |  | — |  |  |  | 16,023 |  |  |  | 16,023 |  |  |  | — |  |  |  | 48,882 |  |  |  | 48,882 |
Net cash provided by/ (used in) investing activities |  |  | (2,387 | ) |  |  | (16,836 | ) |  |  | (19,223 | ) |  |  | (4,550 | ) |  |  | 16,023 |  |  |  | 11,473 |
Total effect on Cash Flow |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
There is no impact on the Group’s Consolidated Statement of Financial Position, Consolidated Statement of Changes in Shareholders’ Deficit, Consolidated Statement of Loss, Net loss per share, Consolidated Statement of Comprehensive Loss, and no impact to financing cash flows for the any of the periods presented.
2.3 | COVID-19
In December 2019, a novel strain of coronavirus (“COVID-19”) emerged. On January 30, 2020, the World Health Organization declared the outbreak a pandemic and a global emergency. In response, many countries and businesses instituted travel restrictions, quarantines, and office closures that are still in place. The extent of the pandemic and governmental responses may impact our ability to obtain raw materials and equipment used for research and development, obtain sufficient additional funds to finance our operations, and conduct clinical trials, any of which could materially and adversely affect our business. Management continues to monitor the situation and enacted significant measures to protect the Group’s supply chain, employees, and the execution of clinical trials. To date, the pandemic has resulted in a slowdown in activities related to the Group’s laboratory operations and at some of its suppliers. The ongoing spread of COVID-19 may also negatively impact the Group’s ability to conduct clinical trials, including potential delays and restrictions on the Group’s ability to recruit and retain patients, principal investigators and healthcare employees. COVID-19 could also affect the operations of contract research organizations, which may also result in delays or disruptions in the supply of product candidates. Immatics continues to expand its clinical programs with additional clinical trial sites opening in the U.S. and in Europe. Due to COVID-19, the Group has also experienced delays in research activities performed under its collaboration agreements. Consequently, the Group recognized less revenue under these agreements in 2020 than previously planned. Management believes the declines in revenue associated with the delay in research activities are largely temporary, as the revenue is primarily associated with non-refundable upfront payments recognized on a cost-to-cost basis. COVID-19 may continue to impact the timing and amount of revenue recognized under these agreements in the future.

X
- Definition The disclosure of the basis used for the preparation of the financial statements. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_10_e&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block. + References No definition available. + Details
Name: | imtx_TextBlockAbstract
Namespace Prefix: | imtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration